By Maureen Testoni June 29, 2021– The year-long dispute over drug companies flouting the 340B statute and denying drug price discounts to hospitals, community health centers, and public health clinics partnering with community pharmacies continues to play out in Washington and in courts around the country. Since last summer, six drug companies – Eli Lilly, Novo Nordisk, … [Read more...]
The Human Toll of Drug Company Restrictions on 340B
May 26, 2021– Anne Webster knew last fall how bad things would get for many of her patients when the drug company Eli Lilly unilaterally pulled out of offering discounts through the 340B drug pricing program on medications dispensed at community pharmacies. As the nurse practitioner at the endocrinology clinic for UnityPoint Health Methodist in Peoria, Ill., she cares for many … [Read more...]
New Federal 340B Order Is Major Step Toward Restoring Drug Discounts
May 19, 2021– The Health Resources & Services Administration (HRSA) has taken decisive action to put a stop to the actions of six drug companies that are denying 340B drug pricing program discounts for medications dispensed at community pharmacies. The action could lead to the end of a nearly year-long dispute pitting for-profit pharmaceutical companies against nonprofit … [Read more...]
Research Highlights the Toll of Drug Maker Attacks on 340B, Shows How Hospitals Use Their Savings to Care for Patients
March 23, 2021– Newly released research demonstrates how patients benefit from the 340B drug pricing program in the form of expanded access and improved health outcomes. But there is growing evidence that the actions of six drug companies to cut off 340B discounts for certain drugs is sapping needed resources during the continued COVID-19 pandemic. 340B Health’s annual … [Read more...]
340B Providers Contemplate the Challenges Met and Prepare for the Ones Ahead
By Maureen Testoni March 11, 2021– In this pandemic-focused world we all find ourselves in, it seems only fitting that one of my highlights of this past month was getting the chance to meet Fauci. No, I’m not talking about the esteemed Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, who has become a household name over the past … [Read more...]
Government Opinion Paves the Way for Reversal of Drug Company Refusals to Provide 340B Discounts
Jan. 8, 2021– While many of us were preparing for an untraditional New Year’s Eve celebration, the federal government made a vitally important announcement about 340B. The administration unequivocally stated that drug companies denying 340B discounts to hospitals, health centers, and clinics that partner with community pharmacies are in violation of federal law. In an … [Read more...]
Drug Industry Report on 340B Attempts a Diversion from Unlawful Manufacturer Actions
October 14, 2020— A new report from the drug industry consultant Berkeley Research Group (BRG) takes aim at community-based pharmacies in the 340B drug pricing program. The report implies, without evidence, that for-profit pharmacy chains are making excessive profits on these arrangements. It ignores the fact that these partnerships provide critical funding for safety-net and … [Read more...]